Schering Plough Articles
Schering-Plough back in profit for 1st-qtr
22 April 2005
Schering-Plough aims for 100B yen sales in Japan by 2010
18 April 2005
Bayer Healthcare looks set to expand in Japan
18 April 2005
Stock Commentary - New York
18 April 2005
S-P's Asmanex cleared in USA for asthma
11 April 2005
UK guide for industry on Rx access in DCs
4 April 2005
Spring allergies impact attention span, memory
4 April 2005
$1B sales milestone for OTC Claritin
4 April 2005
FDA clears Schering-Plough's Temodar
28 March 2005
Ranbaxy reveals restructuring plan
21 March 2005
Vytorin beats Lipitor in high-risk patients
21 March 2005
S-P's Temodal claims big success against glioblastoma
14 March 2005
Appointments at Schering-Plough
14 March 2005
FDA clears S-P's Clarinex 24 Hour
14 March 2005
Integrilin shows 24-hr platelet inhibition
7 March 2005
Myriad starts Ph I study of cancer drug
7 March 2005
Senior promotions and appointments at Schering-Plough
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Editor's views on US profit repatriation, re-importation
7 February 2005
Abbott's RA drug Humira a potential therapy for Crohn's disease?
7 February 2005
Jean-Louis Saillot promoted at Schering-Plough
7 February 2005
Schering-Plough to acquire NeoGenesis
31 January 2005
Stock Commentary - New York
24 January 2005
R&D promotions at Schering-Plough
24 January 2005
ViroPharma gets $6M from S-P in bulk pleconaril deal
17 January 2005
S-P to pay $6M+ to Pa Medicaid program in Claritin pricing case
10 January 2005
Schering-Plough completes expansion of Shiga plant in Japan
10 January 2005
Flamel Tech initiates Medusa Phase I/II trial
10 January 2005
FDA fast-track for J&J/S-P's Remicade
10 January 2005
New use for Schering-Plough's Nasonex
10 January 2005
Norgine announces external appointments and promotions
20 December 2004
Schering-Plough appoints group VP, commercial development
20 December 2004
S-P's Peg-Intron launched in Japan
20 December 2004
Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit
20 December 2004
$10M pleconaril milestone for ViroPharma from S-P
13 December 2004
US appro for Taro's mometasone furoate ointment
13 December 2004
Pedro Barosa named general manager, Schering-Plough, Portugal
22 November 2004
Spain mulling free "morning-after" pill
22 November 2004
Appointments at Myriad Genetics
8 November 2004
Schering-Plough files for Temodal new use in EU
8 November 2004
Priority review for S-P's Temodar sNDA
8 November 2004
Schering-Plough's Peg-Intron OKed in Japan
1 November 2004
Stock Commentary - New York
1 November 2004
Stock Commentary - New York
25 October 2004
S-P's Remicade: EU OK for psoriatic arthritis
25 October 2004
Appointments at Schering-Plough
27 September 2004
Statins to open door for more US OTC switches?
20 September 2004
Stock Commentary - Europe
20 September 2004
Stock Commentary - New York
20 September 2004
Appointments at Schering-Plough Research Institute
20 September 2004
Editor's views on AstaZeneca Exanta woes and Bayer/S-P deal
20 September 2004
Bayer and Schering-Plough form strategic pharmaceuticals alliance
20 September 2004
Shionogi acquires US marketing rights for Cedax
13 September 2004
Tokyo pharma stocks - week to September 6
13 September 2004
Disappointing new data for Merck & Co's Zocor in patients with ACS
6 September 2004
Letter from the Editor
6 September 2004
Massive growth potential of China
6 September 2004
Generex expands JV with PharmaBrand
30 August 2004
S-P exercises option for cold therapy
30 August 2004
Taro Pharma gains FDA OK for generic loratadine syrup
30 August 2004
Tokyo pharma stocks - week to August 16
23 August 2004
Schering-Plough to offer $1.25B of stock
9 August 2004
Stock Commentary - New York
9 August 2004
Schering-Plough promotes Lisa DeBerardine to VP, strategic planning and financial forecasting
9 August 2004
Biogen Idec closes 2nd-qtr above expectations
9 August 2004
Par sees 2nd-qtr 2004 sales rocket 83%
9 August 2004
Stock Commentary - New York
2 August 2004
Appointments at Schering-Plough
2 August 2004
Merck & Co/S-P's Vytorin OKed by FDA
2 August 2004
Stock Commentary - New York
26 July 2004
Merck & Co 2nd-qtr profit dips 2%
26 July 2004
Schering-Plough sees 2nd-qtr losses
26 July 2004
OTC statins "only way for budget-curbed GPs"
26 July 2004
Amdipharm gains UK rights for Detrunorm
26 July 2004
Stock Commentary - New York
19 July 2004
Who suffers least if US Rx price pressure grows?
12 July 2004
Stock Commentary - New York
12 July 2004
Stock Commentary - Tokyo
5 July 2004
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
